Intellia Therapeutics, Inc. (NTLA) Earnings History
Annual and quarterly earnings data from 2014 to 2025
Loading earnings history...
NTLA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
NTLA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | 82.2% | -923.1% | -896.8% |
| 2023 | 75.3% | -1420.5% | -1326.5% |
| 2022 | 85.5% | -879.0% | -909.8% |
| 2021 | 79.2% | -810.4% | -810.5% |
Download Data
Export NTLA earnings history in CSV or JSON format
Free sign-in required to download data
Intellia Therapeutics, Inc. (NTLA) Earnings Overview
As of May 6, 2026, Intellia Therapeutics, Inc. (NTLA) reported trailing twelve-month net income of -$413M, reflecting +27.4% year-over-year growth. The company earned $-3.81 per diluted share over the past four quarters.
Looking at the long-term picture, NTLA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$12M in fiscal 2015.
Intellia Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including EDIT (-$160M net income), CRSP (-$488M net income, -16569.8% margin), BEAM (-$80M net income, -57.2% margin), NTLA has comparable earnings metrics. Compare NTLA vs EDIT →
NTLA Earnings vs Peers
Earnings metrics vs comparable public companies
NTLA Historical Earnings Data (2014–2025)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$413M | +20.5% | $0 | $-3.81 | - | - |
| 2024 | -$519M | -7.9% | -$534M | $-5.25 | -896.8% | -923.1% |
| 2023 | -$481M | -1.5% | -$515M | $-5.42 | -1326.5% | -1420.5% |
| 2022 | -$474M | -77.0% | -$458M | $-6.16 | -909.8% | -879.0% |
| 2021 | -$268M | -99.6% | -$268M | $-3.78 | -810.5% | -810.4% |
| 2020 | -$134M | -34.9% | -$137M | $-2.40 | -231.5% | -235.5% |
| 2019 | -$100M | -16.6% | -$106M | $-1.96 | -230.9% | -246.8% |
| 2018 | -$85M | -26.4% | -$91M | $-1.98 | -280.4% | -298.6% |
| 2017 | -$68M | -113.5% | -$70M | $-1.88 | -258.6% | -266.3% |
| 2016 | -$32M | -155.2% | -$32M | $-0.91 | -192.0% | -195.2% |
See NTLA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NTLA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NTLA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNTLA — Frequently Asked Questions
Quick answers to the most common questions about buying NTLA stock.
Is NTLA growing earnings?
NTLA EPS is $-3.81, with earnings growth accelerating to +27.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-413M.
What are NTLA's profit margins?
Intellia Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are NTLA's earnings?
NTLA earnings data spans 2014-2025. The accelerating earnings trend is +27.4% YoY. Historical data enables comparison across business cycles.